Story perspectives

Pfizer Bets $150M on YaoPharma's Obesity Drug YP05002

12/9/2025

33 5

Summary

Story summary

Pfizer has agreed to pay YaoPharma $150 million for the rights to the experimental obesity drug YP05002, with potential payments reaching $1.94 billion based on milestones.
YaoPharma will conduct Phase 1 trials of YP05002.
Pfizer plans further development and combination studies with its own obesity treatment.
The obesity market is growing and dominated by Eli Lilly and Novo Nordisk, prompting Pfizer's strategic push after COVID-19 product sales challenges.

1 of 1

Story summary

Pfizer has agreed to pay YaoPharma $150 million for the rights to the experimental obesity drug YP05002, with potential payments reaching $1.94 billion based on milestones.
YaoPharma will conduct Phase 1 trials of YP05002.
Pfizer plans further development and combination studies with its own obesity treatment.
The obesity market is growing and dominated by Eli Lilly and Novo Nordisk, prompting Pfizer's strategic push after COVID-19 product sales challenges.